Moricizine

From Self-sufficiency
Jump to: navigation, search
Moricizine
File:Moricizin.svg
Systematic (IUPAC) name
ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate
Clinical data
Pregnancy
category
Pharmacokinetic data
Bioavailability 38%
Protein binding 95%
Biological half-life 3-4 hours (healthy volunteers), 6-13 hours (cardiac disease)
Identifiers
CAS Number 31883-05-3
ATC code none
PubChem CID 34633
DrugBank APRD01124
Chemical data
Formula C22H25N3O4S
Molar mass 427.518 g/mol[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Moricizine is a phenothiazine derivative with Vaughan Williams class Ic antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that moricizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations[citation needed]. Compared with disopyramide and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia[citation needed]. Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. Moricizine appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes moricizine a worthwhile addition to currently available antiarrhythmic agents.

External links


de:Moricizin

it:Moricizina